Epocrates Goes Red
Epocrates (NAS: EPOC) reported earnings on Feb. 28. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Epocrates beat expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank slightly and GAAP earnings per share contracted to a loss.
Margins dropped across the board.
Epocrates booked revenue of $29.7 million. The five analysts polled by S&P Capital IQ predicted a top line of $28.1 million on the same basis. GAAP reported sales were 1.9% lower than the prior-year quarter's $30.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.05. The five earnings estimates compiled by S&P Capital IQ predicted $0 per share on the same basis. GAAP EPS were -$0.27 for Q4 versus $0.18 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 60.6%, 1,170 basis points worse than the prior-year quarter. Operating margin was -6.5%, 1,900 basis points worse than the prior-year quarter. Net margin was -22.0%, 3,080 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $28.7 million. On the bottom line, the average EPS estimate is $0.03.
Next year's average estimate for revenue is $119.0 million. The average EPS estimate is $0.22.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 34 members out of 38 rating the stock outperform, and four members rating it underperform. Among 10 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), eight give Epocrates a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Epocrates is hold, with an average price target of $12.50.
Over the decades, small-cap stocks like Epocrates have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Epocrates to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.